Proteogenomics decodes the evolution of human ipsilateral breast cancer
Artikel i vetenskaplig tidskrift, 2023
Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic determinants of molecular tumor evolution. Our analyses revealed a relationship between hormonal receptors status and proliferation levels resulting in the gain of somatic mutations and copy number. This in turn re-programmed the transcriptome and proteome towards a highly replicating and genomically unstable IBTRs, possibly enhanced by APOBEC3B. In order to investigate the origins of IBTRs, a second analysis that included primaries with no recurrence pinpointed proliferation and immune infiltration as predictive of IBTR. In conclusion, our study shows that breast tumors evolve into different IBTRs depending on hormonal status and proliferation and that immune cell infiltration and Ki-67 are significantly elevated in primary tumors that develop IBTR. These results can serve as a starting point to explore markers to predict IBTR formation and stratify patients for adjuvant therapy.
Författare
Tommaso De Marchi
Lunds universitet
Paul Theodor Pyl
Science for Life Laboratory (SciLifeLab)
Martin Sjöström
University of California
Lunds universitet
Susanne Reinsbach
Chalmers, Life sciences, Systembiologi
Sebastian DiLorenzo
Uppsala universitet
Björn Nystedt
Uppsala universitet
Lena Tran
Lunds universitet
Gyula Pekar
Lunds universitet
Fredrik Wärnberg
Göteborgs universitet
Irma Fredriksson
Karolinska Institutet
Karolinska universitetssjukhuset
Per Malmström
Lunds universitet
Skånes universitetssjukhus (SUS)
Mårten Fernö
Lunds universitet
Lars Malmström
Lunds universitet
Johan Malmstöm
Lunds universitet
Emma Niméus
Skånes universitetssjukhus (SUS)
Lunds universitet
Communications Biology
23993642 (eISSN)
Vol. 6 1 139Ämneskategorier
Medicinsk genetik
Urologi och njurmedicin
Cancer och onkologi
DOI
10.1038/s42003-023-04526-6
PubMed
36732562